| Lenalidomide | hsa00051 | Fructose and mannose metabolism | 4.48E-02 | 1 | P19367 | HK1 | More | |
| Lenalidomide | hsa00052 | Galactose metabolism | 4.48E-02 | 1 | P19367 | HK1 | More | |
| Lenalidomide | hsa00500 | Starch and sucrose metabolism | 3.60E-02 | 1 | P19367 | HK1 | More | |
| Lenalidomide | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 9.10E-03 | 1 | P19367 | HK1 | More | |
| Lenalidomide | hsa00561 | Glycerolipid metabolism | 4.48E-02 | 1 | Q16760 | DGKD | More | |
| Lenalidomide | hsa00562 | Inositol phosphate metabolism | 4.28E-02 | 2 | Q14642, P19174 | INPP5A, PLCG1 | More | |
| Lenalidomide | hsa04012 | ErbB signaling pathway | 4.28E-02 | 2 | Q13191, P19174 | CBLB, PLCG1 | More | |
| Lenalidomide | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Lenalidomide | hsa04122 | Sulfur relay system | 9.10E-03 | 1 | O95396 | MOCS3 | More | |
| Lenalidomide | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | |
| Lenalidomide | hsa04151 | PI3K-Akt signaling pathway | 4.83E-02 | 2 | Q14738, P62873 | PPP2R5D, GNB1 | More | |
| Lenalidomide | hsa04213 | Longevity regulating pathway - multiple species | 8.73E-03 | 3 | Q9Y4H2, P11142, Q13547 | IRS2, HSPA8, HDAC1 | More | |
| Lenalidomide | hsa04340 | Hedgehog signaling pathway | 2.62E-02 | 2 | O43791, P30279 | SPOP, CCND2 | More | |
| Lenalidomide | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Lenalidomide | hsa04612 | Antigen processing and presentation | 3.21E-02 | 3 | Q13241, P01732, P11142 | KLRD1, CD8A, HSPA8 | More | |
| Lenalidomide | hsa04613 | Neutrophil extracellular trap formation | 1.31E-02 | 4 | P19174, P11215, Q13547, P62807 | PLCG1, ITGAM, HDAC1, HIST1H2BC | More | |
| Lenalidomide | hsa04650 | Natural killer cell mediated cytotoxicity | 2.94E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | |
| Lenalidomide | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Lenalidomide | hsa04728 | Dopaminergic synapse | 7.84E-03 | 2 | P62873, Q14738 | GNB1, PPP2R5D | More | |
| Lenalidomide | hsa04740 | Olfactory transduction | 3.60E-02 | 1 | P62873 | GNB1 | More | |
| Lenalidomide | hsa04744 | Phototransduction | 2.71E-02 | 1 | P62873 | GNB1 | More | |
| Lenalidomide | hsa04910 | Insulin signaling pathway | 1.67E-02 | 3 | Q14642, Q13191, Q9Y4H2 | INPP5A, CBLB, IRS2 | More | |
| Lenalidomide | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | |
| Lenalidomide | hsa04930 | Type II diabetes mellitus | 3.60E-02 | 1 | P19367 | HK1 | More | |
| Lenalidomide | hsa04973 | Carbohydrate digestion and absorption | 3.60E-02 | 1 | P19367 | HK1 | More | |
| Lenalidomide | hsa05134 | Legionellosis | 3.60E-03 | 3 | P11215, P11142, P19875 | ITGAM, HSPA8, CXCL2 | More | |
| Lenalidomide | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
| Lenalidomide | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
| Lenalidomide | hsa05203 | Viral carcinogenesis | 8.26E-03 | 4 | P30279, Q13547, Q15283, P62807 | CCND2, HDAC1, RASA2, HIST1H2BC | More | |
| Lenalidomide | hsa05206 | MicroRNAs in cancer | 1.63E-02 | 4 | P30279, Q9Y4H2, Q13547, P19174 | CCND2, IRS2, HDAC1, PLCG1 | More | |
| Lenalidomide | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
| Lenalidomide | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | |
